4.4 Article

Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant

Related references

Note: Only part of the references are listed.
Review Biotechnology & Applied Microbiology

Vaccine-associated Rubella - a report of two cases and a review of the literature

Sean Wei Xiang Ong et al.

Summary: Two adult patients presented with a typical erythematous rash consistent with rubella disease after MMR vaccination. Both patients had an uncomplicated clinical course, with one confirmed to have vaccine-associated rubella and the other having a positive pharyngeal swab for rubella virus PCR matching the vaccine strain. Further study is needed to determine the incidence, risk factors, and clinical characteristics of rubella vaccine-strain related disease.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

Letter Hematology

Early loss of immunity against measles following allogeneic hematopoietic stem cell transplantation

Hannah M. Garcia Garrido et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Article Immunology

Vaccine Rubella: A Rare Cause of Post-transplant Hematopoietic Death, but a Major Public Health Problem

Marta Gonzalez Vicent et al.

OPEN FORUM INFECTIOUS DISEASES (2018)

Review Immunology

Immune Reconstitutional after Allogeneic Hematopoietic Stem Cell Transplantation

Justyna Ogonek et al.

FRONTIERS IN IMMUNOLOGY (2016)

Article Immunology

2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

Lorry G. Rubin et al.

CLINICAL INFECTIOUS DISEASES (2014)

Article Biophysics

Early measles vaccination in bone marrow transplant recipients

CM Machado et al.

BONE MARROW TRANSPLANTATION (2005)